First and foremost, tell us what Halo's
aim is, because it's fascinating. It's, for example, those that many of us
are affected by cancer. You're trying to target the way in which
we are treated with chemotherapy and

make it easier.
Quicker. Yes, exactly.
Thank you for having us here. Yes, We are a biotech company based in
San Diego, and we have a drug delivery platform for subcutaneous drug delivery.
We license it to leading companies like

Roche and Bristol-Myers Squibb and
Janssen, and they can transform their intravenous therapies for cancer and
autoimmune disease that generally has to be given in hour long infusions and an
infusion sweep into a simple, short 3 to

5 minute subcutaneous injection under
the skin. Often that means the patient doesn't have to
travel to a big hospital for it. They can have it in the doctor's office
or with some of our treatments even at home.
And so you can imagine that there's

transformative for the patient, for the
caregiver who's having to do all the travel coordination.
But it also saves the health care system.
And it's a very large and growing business.
We expect revenues of about $1,000,000,000 this year, $600 million
in EBITDA.

And so it's a very attractive growing
business throwing off cash, hence our interest in using that cash to further
accelerate our growth. So why therefore buy a company that does
drug discovery, does drug manufacturing? Yeah, there's some core principles that
you can imagine that our business is a

licensing business.
We go to the pharma companies and we license them our technology at the core.
That's what Evotec does as well. It does it with drug discovery.
So they have a mission to invent more effective medicines, but they'll do that
with partners, same partners as us and

even larger number of partners.
And they also have got manufacturing where they want to be the manufacturer
using a new process that's called continuous manufacturing that will
deliver higher quality, a lower cost again, for those same partners.
So by adding two additional divisions of

strong revenue growth and EBIT
contribution, you can imagine that's a great combination for healing, same
similar business model, similar principle that we want to be the best
partner with, the most innovative and best technologies.
I think to throw the market off a little

bit, Evotec itself has been pretty
beaten up over the year, down 59%. That's why private equity has been
eyeing it. You're eyeing it.
What do you think the market isn't getting because you've now explain that
you're paying for it in cash.

So it's not going to be a liquidation in
an issue from a erosion of value from the share price perspective.
What now do you need to convince investors of?
Yeah, certainly there were some recent headwinds, but we think those are
definitely past as we have conducted a

lot of customer interviews to understand
how Evotec's platforms are seen and how they're going to be used for the future.
And so we see this as Evotec is poised for growth at this point in time.
I think in talking to investors and this

This is day two of us talking to investors, and there's really beginning to be an appreciation for the unique combination that this would create. We would create a leading pharma services company with well above average gross margins forever. I mean, that's very attractive.

Obviously, for what you can do with that cash to further fuel growth and also durable revenues for a very long time into the next decade and beyond. It's interesting that the timing... Is this a moment that it's good to do...

M&A, cross-border M&A? Was you aware of the fact that people are thinking M&A is going to be easier in the next administration? I know we have been working for a couple of years actually to find the right acquisition to use our cash to return value to shareholders.

This comes after months of research with, as I say, more than 50 customers of Evotec to consulting groups. We have been looking for the right combination and we have very strict criteria, and Evotec hits it in terms of growth of revenue, growth of either out pharmaceutical partners, de-risk

businesses. It is just a terrific fit, and we're going to have the opportunity to grow by cross-selling platforms to all of the current partners. If it takes us over 500 partners, we have about ten. But also by having the best and the most

diverse platform now that goes end to end will attract new partners, new people who hadn't worked with Evotec before. So that's where the growth will come both from within expansion, but also new partners too.

Halozyme CEO: Evotec Is Poised for Growth

Welcome to the Bloomberg Technology YouTube channel. Subscribe for original series and mini-docs on game-changing technologies, profiles on innovators, live conversations with experts, and breaking technology news & analysis from Bloomberg TV.

Halozyme CEO: Evotec Is Poised for Growth

Halozyme CEO: Evotec Is Poised for Growth

Scripts